Garcinia extract-containing composition, method for reducing body fat

Abstract

The present invention provides an extract-containing composition that ensures safety and exhibits excellent effects in reducing body fat in healthy adults. [Solution] A composition used to promote the reduction of body fat, wherein the composition contains Garcinia extract as an active ingredient, and the Garcinia extract contains hydroxycitric acid and / or a salt thereof in an amount equivalent to 200-300 mg of hydroxycitric acid per day.

Description

[[Technical Field]]

[0001] The present invention relates to a Garcinia extract-containing composition, and more particularly to a Garcinia extract-containing composition with guaranteed safety and excellent effect of reducing body fat in healthy adults. [[Background Art]]

[0002] In recent years, obesity and increased body fat have attracted attention as major risk factors for lifestyle-related diseases, and foods and supplements for the prevention and improvement thereof have been developed. Conventionally, exercise therapy and dietary restriction are generally recommended as means for reducing body fat, but these are difficult to sustain over the long term, and there is a demand for an auxiliary method that can be implemented more easily.

[0003] Against this background, development of compositions using specific plant-derived extracts and functional ingredients is underway. For example, hydroxycitric acid (HCA), which is abundantly contained in the rind of Garcinia cambogia, is known as a compound having a fat-reducing effect. HCA inhibits ATP-citrate lyase, prevents the conversion of excess sugar into fat and its accumulation, and promotes the breakdown of accumulated fat via activation of carnitine acyltransferase (CPT1). In clinical trials, it has been reported that intake of 250 to 500 mg of HCA per day promotes fat oxidation, and intake of 750 to 3450 mg of HCA reduces visceral fat and subcutaneous fat, respectively (for example, Non-Patent Documents 1 and 2). [[Prior Art Documents]] [[Non-Patent Documents]]

[0004] [[Non-Patent Document 1]] Lim, K. et al., "Intake of (-)-hydroxycitric acid increases fat utilization during exercise in untrained women", J. Nutr. Sci. Vitaminol., 2003, Vol. 49, pp. 163-167 [Non-Patent Document 2] Onomura, K. et al., "Subgroup analysis study on the effects of long-term intake of garcinia extract-containing jelly beverages on body fat mass," Med.Consult.New Remedies, 2020, Vol. 57, pp. 1087-1092. [Overview of the project] [Problems that the invention aims to solve]

[0005] However, in previous studies, high doses of 750 mg or more per day were commonly used to evaluate the fat-reducing effects of HCA. Such continuous intake of high doses posed a significant challenge in terms of patient adherence. On the other hand, while a fat-burning effect has been confirmed with a daily intake of 250-500 mg of HCA, the effect of long-term administration at this dose on reducing body fat has not yet been clarified.

[0006] The present invention aims to provide an extract-containing composition that ensures safety and exhibits excellent effects in reducing body fat in healthy adults. [Means for solving the problem]

[0007] However, in light of these circumstances, the inventors diligently conducted research and found that a sufficient reduction in body fat can be obtained by long-term intake of a low dose of HCA of 200-300 mg per day, thus completing the present invention.

[0008] In other words, the present invention has the following aspects. [1] A composition used for the purpose of promoting the reduction of body fat, The above composition contains Garcinia extract as an active ingredient, A Garcinia extract-containing composition wherein the Garcinia extract contains hydroxycitric acid and / or its salts in an amount equivalent to 200-300 mg of hydroxycitric acid per day. [2] The Garcinia extract-containing composition according to [1], wherein the Garcinia extract contains hydroxycitric acid and / or a salt thereof in an amount equivalent to 250 mg of hydroxycitric acid per day. [3] The garcinia extract-containing composition according to [1] or [2], wherein the garcinia extract contains less than 25 mg of garcinol as a daily dose. [4] The garcinia extract-containing composition according to any one of [1] to [3], wherein the garcinia extract contains a salt of hydroxycitric acid, and the salt of hydroxycitric acid is a salt of hydroxycitric acid and at least one of alkali metal (B1) and alkaline earth metal (B2) (B). [5] The Garcinia extract-containing composition according to any one of [1] to [4], wherein the Garcinia extract contains 5% by mass or more of at least one of the alkali metal (B1) and alkaline earth metal (B2) (B). [6] The garcinia extract-containing composition according to any one of [1] to [5], wherein the garcinia extract contains 0.5% by mass or more of calcium and / or magnesium as the alkaline earth metal (B2). A method for reducing body fat, comprising administering any of the compositions described in [7] [1] to [6] for 12 weeks or more. [Effects of the Invention]

[0009] This invention allows for sufficient body fat reduction effects to be achieved with long-term intake of HCA at a lower dose compared to conventional methods, thereby significantly reducing the burden on the user while safely and reliably achieving excellent body fat reduction effects. [Brief explanation of the drawing]

[0010] [Figure 1] This is a flowchart for selecting testers to participate in the evaluation of the embodiment. [Figure 2] (a) to (c) are graphs showing the changes in fat area for each of the examples and comparative examples. [Modes for carrying out the invention]

[0011] Hereinafter, the present invention will be described based on examples of embodiments for carrying out the present invention. However, the present invention is not limited to the embodiments described below.

[0012] In the present specification, the expression "x and / or y (where x and y are any components)" means at least one of x and y, and encompasses three cases: only x, only y, and both x and y. In the present specification, when the expression "X to Y" (where X and Y are any numerical values) is used, unless otherwise stated, it means "not less than X and not more than Y", and also includes the meaning of "preferably greater than X" or "preferably less than Y". In the present specification, when the expressions "not less than X" (where X is any numerical value) or "not more than Y" (where Y is any numerical value) are used, they also include the meaning of "preferably greater than X" or "preferably less than Y", respectively. Regarding the stepwisely described numerical ranges in the present specification, the upper limit or lower limit of the numerical range of one step can be arbitrarily combined with the upper limit or lower limit of the numerical range of another step. Further, in the numerical ranges described in the present specification, the upper limit or lower limit of the numerical range can also be replaced with the values shown in the examples.

[0013] In the present specification, the expression "contained as an active ingredient" means that the garcinia extract is contained in the composition in an effective amount that exerts a body fat reducing effect. Here, the "effective amount that exerts a body fat reducing effect" means an amount at which a statistically significant reduction in body fat is observed compared to that before administration when the present composition is continuously administered for 12 weeks or more. Note that the evaluation of body fat reduction uses, as an indicator, that a significant reduction is observed compared to before administration in at least one measurement value of body weight, BMI, body fat percentage, waist circumference, or visceral fat area.

[0014] A composition containing a Garcinia extract according to an embodiment of the present invention (hereinafter may be referred to as "the composition") is a composition used for the purpose of promoting reduction of body fat, which contains a Garcinia extract (A), wherein the Garcinia extract contains hydroxycitric acid and / or a salt thereof in an amount equivalent to 200 to 300 mg of hydroxycitric acid as a daily dose. Details will be described below.

[0015] <Garcinia extract (A)> The Garcinia extract (A) used in the present embodiment includes components extracted from fruits, seeds, bark, or other parts of plants of the genus Garcinia. In particular, those extracted from fruits are preferred, and those extracted from pericarp are more preferred. Examples of the plants of the genus Garcinia include Garcinia cambogia, Garcinia indica, and the like, and among these, those derived from Garcinia cambogia are preferred.

[0016] The Garcinia extract (A) used in the present embodiment is water-soluble, which facilitates digestion and absorption and improves bioavailability. Here, in the present specification, "water-soluble" means, for example, that the amount of water required to dissolve 1 g of the extract at 25°C is less than 10 mL, and the extract falls under either "extremely soluble" or "soluble" in the solubility criteria of the Japanese Pharmacopoeia.

[0017] The Garcinia extract (A) can be obtained, for example, by drying and pulverizing fruits, seeds, or bark of a plant of the genus Garcinia, performing extraction with an aqueous solvent (e.g., water, ethanol, etc.), and then subjecting the extract to filtration, concentration, and drying steps. It can also be obtained as commercially available Garcinia Powder J or Garcinia Powder MS (both manufactured by Nippon Shinyaku Co., Ltd.).

[0018] In the composition of this embodiment, the content of Garcinia extract (A) is preferably, for example, 0.0005 to 99.5% by mass, more preferably 0.005 to 90% by mass, and even more preferably 0.05 to 84% by mass, from the viewpoint of ease of administration.

[0019] The Garcinia extract (A) contains HCA and / or its salts, and the daily dose as an HCA equivalent can be in the range of 10 to 1500 mg, more preferably 25 to 1000 mg, even more preferably 50 to 750 mg, particularly preferably 100 to 500 mg, and most preferably 200 to 300 mg.

[0020] In this embodiment, it is preferable to use a garcinia extract (A) that contains HCA and further contains a salt of at least one of alkali metals (B1) and alkaline earth metals (B2) (B), as this improves dispersibility and enhances the absorption of the garcinia extract (A). Furthermore, in this embodiment, it is particularly preferable to use a salt of HCA contained in the Garcinia extract (A) that includes a salt of HCA with at least one of alkali metals (B1) and alkaline earth metals (B2) (B), as this improves dispersibility and enhances the absorption of the Garcinia extract (A).

[0021] In this specification, "contained in Garcinia extract" means that the components of the Garcinia extract are not limited to those derived from the Garcinia plant, but also include components added during the extraction process that remain in the final extract.

[0022] <At least one of alkali metals (B1) and alkaline earth metals (B2) (B)> Examples of alkali metals (B1) or alkaline earth metals (B2) can be used, such as the following:

[0023] (Alkali metal (B1)) Examples of alkali metals (B1) used in this embodiment include sodium, potassium, lithium, rubidium, and cesium. Examples of compounds used to form a salt between HCA and alkali metal (B1) include sodium hydroxide or potassium hydroxide. Since the composition of this embodiment can be used as a food product, it is desirable to appropriately select a compound that can be incorporated into food products as the compound used to form the salt with HCA. As salts of HCA and alkali metal (B1), sodium salts and potassium salts are particularly preferred because they can be used without impairing the flavor or functionality of the food.

[0024] (Alkaline earth metal (B2)) Examples of alkaline earth metals (B2) used in this embodiment include calcium, magnesium, strontium, barium, and radium. Examples of compounds used to form salts between HCA and alkaline earth metals (B2) include calcium hydroxide and magnesium hydroxide. Since the composition of this embodiment can be used as a food product, it is desirable to appropriately select a compound that can be incorporated into food products as the compound used to form the salt with HCA. As salts of HCA and alkaline earth metals (B2), calcium salts and magnesium salts are particularly preferred because they are also used as nutritional supplements in food.

[0025] The garcinia extract (A) used in the composition of this embodiment preferably contains 1 to 50% by mass of at least one of alkali metals (B1) and alkaline earth metals (B2) (B), more preferably 5 to 20% by mass, and even more preferably 7 to 13% by mass. It is preferable that the content of at least one of alkali metals (B1) and alkaline earth metals (B2) (B) is set within the above range, as this improves dispersibility and enhances the water solubility of the garcinia extract (A).

[0026] In particular, when calcium and / or magnesium are included in the alkaline earth metal (B2) at a concentration of 0.5% by mass or more, the dispersibility tends to improve, it is preferable that calcium and / or magnesium are included at a concentration of 5 to 20% by mass, and even more preferably at a concentration of 7 to 13% by mass.

[0027] The pH of the Garcinia extract (A) used in the composition of this embodiment is preferably 7 or less, as this increases the number of free carboxyl groups of HCA and further improves water solubility. It is more preferably 3 to 7, even more preferably 4 to 7, and particularly preferably 4 or more and less than 7, as this improves the stability of HCA and facilitates digestion and absorption in the stomach. The pH value mentioned above was measured using a 1% w / v solution prepared with ultrapure water at room temperature (around 25°C).

[0028] The content of alkali metal (B1) and alkaline earth metal (B2) in the composition of this embodiment can be determined, for example, by inductively coupled plasma emission spectrometry, atomic absorption spectrometry, X-ray fluorescence spectrometry, titration (EDTA titration), etc.

[0029] (Garcinol) In this specification, "garcinol" refers to a polyphenol compound found in plants of the genus Garcinia, with chemical formula C 38 H 50 This is indicated by O6. Since the aforementioned garcinol is lipid-soluble, it is clearly distinguished from the water-soluble garcinia extract used in the present invention. In this embodiment, in order to ensure the water solubility of the garcinia extract, the content of garcinol, which is lipid-soluble, is preferably 4.2% by mass or less, more preferably 2% by mass or less, even more preferably 1% by mass or less, and even more preferably none at all. Furthermore, the Garcinia extract used in this embodiment preferably contains less than 25 mg of garcinol per day, more preferably less than 10 mg, even more preferably less than 1 mg, and may contain no garcinol at all.

[0030] The present invention relates to a composition in which a water-soluble Garcinia extract (A) has been found to have the effect of promoting the reduction of body fat. Therefore, garcinol, being lipid-soluble, is not essential. However, this does not mean that the presence of garcinol inhibits the body fat reduction effect. In other words, because the present invention does not require lipid-soluble garcinol as an essential component, the composition is simpler and tends to have improved uniformity.

[0031] (Other materials) In addition to the Garcinia extract (A) and at least one of alkali metals (B1) and alkaline earth metals (B2) (B), the composition of this embodiment may optionally contain, for example, nutritional supplements, auxiliary functional components, excipients / stabilizers, flavor / palatability enhancing components, and formulation components, for the purpose of improving the stability, enhancing the function, and improving palatability during ingestion of the composition. By appropriately blending these components, the composition of this embodiment can exert an effect of reducing body fat, while also improving stability and ease of ingestion, making it possible to provide a more practical product.

[0032] (Nutritional supplements) Since the composition of this embodiment can be used in foods intended for maintaining health and supplementing nutrition, it can optionally contain, for example, vitamins such as vitamin C, vitamin E, and B vitamins (B1, B2, B6, B12), minerals such as iron, zinc, selenium, and copper, and amino acids and their derivatives such as L-carnitine, glutamine, arginine, and leucine.

[0033] (Auxiliary functional ingredients) To complement or synergistically enhance the effects of the composition of this embodiment, for example, polyphenols such as catechin, quercetin, anthocyanin, and resveratrol; lipid metabolism promoting components such as conjugated linoleic acid (CLA), medium-chain fatty acids (MCT oil), EPA, and DHA; plant-derived extracts such as oolong tea extract and Gymnema sylvestre extract; and dietary fibers such as indigestible dextrin, inulin, and β-glucan may be optionally used.

[0034] (Stabilizer) To ensure the physical and chemical stability of the composition of this embodiment and to maintain its appropriate shape and properties, thickeners and gelling agents such as sodium alginate, pectin, and xanthan gum; emulsifiers such as lecithin and sucrose fatty acid esters; pH adjusters such as citric acid, malic acid, and sodium bicarbonate; and antioxidants such as ascorbic acid (vitamin C) and tocopherol (vitamin E) may be optionally used.

[0035] (Ingredients that improve flavor and palatability) When commercializing the composition of this embodiment as a beverage, food, or supplement, ingredients such as sweeteners like sucralose, stevia, and xylitol, and flavorings like vanilla, citrus, and mint can be optionally used to improve palatability.

[0036] (Ingredients for formulation) Since the composition of this embodiment can be provided in various forms such as tablets, capsules, powders, and liquids, appropriate components can be optionally used for each form, such as excipients like lactose, dextrin, and cellulose; disintegrants like croscarmellose sodium and carboxymethylcellulose; and coating agents like hypromellose and shellac. Furthermore, if these components fall under at least one (B) of alkali metals (B1) and alkaline earth metals (B2), the content of these components can be included in the content of at least one (B) of alkali metals (B1) and alkaline earth metals (B2).

[0037] The composition of this embodiment can be manufactured, for example, as follows. In other words, the essential component Garcinia extract (A) and these optional components, as needed, can be mixed by conventional methods, and the shape can be adjusted according to the intended use.

[0038] The composition of this embodiment contains components that promote the metabolism of fat cells, suppress fat accumulation, and promote fat burning, and can be used for diet support, prevention or improvement of obesity, weight management, and improvement of sports performance. Therefore, it can be applied to a wide range of products, including health foods, beverages, supplements, pharmaceutical compositions, and animal feed. Furthermore, its shape is not particularly limited and it can be provided as tablets, granules, powders, jellies, gums, gums, liquids, syrups, etc. The granular and powdered formulations include powdered beverages, and the liquid formulations include soft drinks, nutritional drinks, fruit juices, tea beverages, coffee beverages, dairy beverages, etc. Furthermore, they can also be used as general food products such as cookies, biscuits, snacks, and chocolates. A composition containing hydroxycitric acid and / or its salt in an amount equivalent to 200-300 mg of hydroxycitric acid may be multiple tablets if the composition of this embodiment is in tablet form. [Examples]

[0039] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the following examples unless it exceeds the gist of the invention. In the examples, "parts" and "%" refer to mass.

[0040] The following materials were prepared for the creation of the examples and comparative examples. • Garcinia extract: Garcinia Powder J (manufactured by Nippon Shinyaku Co., Ltd.) Calcium stearate • Microcrystalline cellulose • Powdered reduced maltose syrup Partially pregelatinized starch • Fine-grained silicon dioxide • Powdered caramel coloring • Gardenia yellow pigment

[0041] The prepared materials were used to create tablets for the examples and comparative examples, according to the formulations shown in Table 1 below. The comparative tablets have caramel coloring and gardenia yellow pigment added to them so that they are indistinguishable in appearance.

[0042] [Table 1]

[0043] To evaluate the effects of oral administration of the obtained examples and comparative examples on reducing visceral fat area, subcutaneous fat area, and total abdominal fat area (visceral fat + subcutaneous fat), a placebo-controlled, randomized, double-blind, parallel-group comparative study was conducted. Study participants were randomly assigned to Example 1 (test composition group) and Comparative Example 1 (placebo group) in a 1:1 ratio, using age, sex, BMI, and visceral fat area as allocation adjustment factors. The eligibility criteria for the aforementioned test participants are as follows: Japanese men and women aged 20 to under 65. BMI between 23 and 30. • Individuals who can keep an electronic diary using a smartphone or PC. • The participant must understand the research content and provide written consent to participate. Furthermore, the exclusion criteria are as follows: • Individuals currently receiving treatment at a medical institution or who regularly take medication (including herbal medicine). • Individuals receiving dietary therapy or exercise therapy under the guidance of a physician. • Individuals with a history of or current serious illness. • Individuals with a history of gastrointestinal surgery (excluding appendicitis). • Individuals who regularly use obesity-related health foods or supplements. • Individuals with excessive drinking habits. • Pregnant, breastfeeding, or planning to become pregnant.

[0044] <Placebo-controlled, randomized, double-blind, parallel-group comparative trial> Participants in the study were instructed to take either Example 1 or Comparative Example 1, three tablets once a day before breakfast, with water. If they forgot to take the tablet before breakfast, they were instructed to take it before lunch or dinner on the same day, and carrying it over to the next day was prohibited. Study participants submitted dietary records at baseline and for the three days prior to examinations at weeks 4, 8, and 12 of the intake regimen. Based on these dietary records, nutrient intake and energy intake were calculated. The following items (CT scan, blood test, physical examination) were measured. The results obtained were statistically analyzed as shown below.

[0045] [Statistical analysis] Statistical analysis was performed using R (ver. 4.2) and SPSS Statistics (ver. 29). Data are presented as mean ± standard deviation. Measurements at weeks 4, 8, and 12 were evaluated using analysis of covariance (ANCOVA), with the measured values ​​as the dependent variable, the intervention (test food or placebo) as the fixed effect, and the measured values ​​at screening as the covariate. A p-value of less than 0.05 was considered statistically significant. Although there were no dropouts from the start to the end of the study, one participant who became pregnant during the study period was excluded from the efficacy analysis. In addition, 19 participants who met the exclusion criteria due to excessive alcohol consumption, significant changes in lifestyle (overeating and drinking, significantly increased exercise for more than one-third of the study period, etc.), daily snacking, and no exercise habits were excluded, and ultimately 20 participants were selected for the efficacy analysis (Figure 1).

[0046] [CT scan] First, Table 2 below shows the visceral fat area, subcutaneous fat area, and total abdominal fat area (visceral fat + subcutaneous fat) of the selected study participants, as measured by CT scans.

[0047] [Table 2]

[0048] The results in Table 2 show that for the 20 participants selected for efficacy analysis, no significant difference in background data was observed between Example 1 and Comparative Example 1 at baseline (week 0). This indicates that the comparison between Example 1 and Comparative Example 1 in this study system can appropriately reflect the influence of Example 1.

[0049] (Body fat assessment) Figure 2 shows a comparison of the visceral fat area, subcutaneous fat area, and total abdominal fat area (visceral fat + subcutaneous fat) obtained from the aforementioned CT scan at baseline (week 0) and week 12 of intake. The results in Figure 2 show that there was no significant decrease in visceral fat area or subcutaneous fat area between Example 1 and Comparative Example 1. However, in terms of total fat area (visceral fat + subcutaneous fat), Comparative Example 1 was 12.57 cm² after 12 weeks. 2 An increase was observed, but in Example 1, it was 22.47 cm. 2 A decrease was confirmed. Since this change is significantly greater in Example 1 than in Comparative Example 1, it can be said that in Example 1, continuous fat burning over 12 weeks led to a reduction in body fat.

[0050] Next, in order to confirm the safety of the composition of this embodiment, blood tests and physical examinations were performed as follows.

[0051] [Blood test] Blood tests were performed on study participants at baseline (week 0), and at weeks 4, 8, and 12 of the intake regimen. The following parameters (hematological and biochemical) were measured. The results are shown in Tables 3 and 4 below.

[0052] (Hematological tests) The results of the hematological tests, which included measuring red blood cell count, white blood cell count, hemoglobin, hematocrit, platelet count, and white blood cell differential (neutrophils, eosinophils, basophils, monocytes, and lymphocytes), are shown in Table 3 below.

[0053] [Table 3]

[0054] (Biochemical tests) The results of the biochemical tests, which measured total protein, triglycerides, total cholesterol, HDL cholesterol, LDL cholesterol, ALP, AST, ALT, γ-GTP, LDH, uric acid, urea nitrogen, total bilirubin, albumin, creatinine, fasting blood glucose (FBS), HbA1c, and glycated albumin, are shown in Table 4 below.

[0055] [Table 4]

[0056] The results in Tables 3 and 4 show that no significant changes were observed in hematological and biochemical test parameters between Example 1 and Comparative Example 1 during the study period. This indicates that the intake of Example 1 is safe.

[0057] [Physical examination] Systolic blood pressure, diastolic blood pressure, and pulse rate were measured for study participants at baseline and at weeks 4, 8, and 12 of the initiation of supplementation. The results are shown in Table 5 below.

[0058] [Table 5]

[0059] As shown in Table 5, no significant changes were observed in systolic blood pressure, diastolic blood pressure, or pulse rate between Example 1 and Comparative Example 1 during the study period. This indicates that the intake of Example 1 is safe.

[0060] As shown in Figures 2(a) to 2(c), the results of this embodiment indicate that the composition of this embodiment has the effect of reducing body fat in healthy adults who maintain a proper diet. In other words, while it had been previously confirmed that administering 250 mg of HCA per day promoted fat burning through a decrease in the respiratory quotient, the actual body fat reduction effect of such low doses had not been clarified. However, the results shown in Figures 2(a) to (c) revealed a clear correlation between the duration of administration and the body fat reduction effect.

[0061] Specifically, while a decrease in the respiratory quotient was observed within the first five days of administration, no significant reduction in body fat mass was observed. It became clear that a statistically significant reduction in body fat was only achieved after continuous administration for 12 weeks or more. This suggests that the reduction in body fat achieved by low-dose HCA administration in this invention is achieved not through temporary metabolic changes, but through sustained metabolic regulation. Therefore, unlike conventionally known short-term fat-burning effects, the present invention is based on a novel and useful technical concept of substantial body fat reduction through long-term administration at low doses.

[0062] Furthermore, as shown in Tables 3-5, no safety issues were identified, indicating that the composition of this embodiment is highly safe.

[0063] Next, we will examine the relationship between the pH of Garcinia extract and its solubility in water. First, we prepared two types of Garcinia extract with different pH levels (Garcinia Powder J and Garcinia Powder CR, both manufactured by Nippon Shinyaku Co., Ltd.). The pH of Garcinia powder J is in the range of 4 to 7, and the pH of Garcinia powder CR is in the range of 9 to 11. The difference in pH of the Garcinia extracts is due to the difference in the amount of calcium added during the process of preparing the Garcinia extract by adding calcium to the Garcinia extract (which is acidic because HCA is present in its free form) to form a calcium salt. In other words, when the amount of calcium added is small, the acidity is maintained, while when it is large, it becomes alkaline. Next, the prepared Garcinia extracts were each prepared as solutions with ultrapure water to a concentration of 10% w / v or higher, and the following samples (I) and (II) were prepared. Sample (I): Garcinia extract with a pH of 4-7 Sample (II): Garcinia extract with a pH of 9-11

[0064] After allowing each prepared sample to stand for 1 hour, its water solubility is evaluated by visual observation and absorbance measurement at a wavelength of 660 nm. As a result, no precipitate was observed in sample (I): Garcinia extract (pH 4-7), and the absorbance at a wavelength of 660 nm was found to be similar to that of ultrapure water. This is thought to be because HCA readily exists as a free form in sample (I) and has high water solubility. On the other hand, in sample (II): Garcinia extract (pH 9-11), precipitation occurred, and the absorbance at a wavelength of 660 nm was found to be significantly higher than that of ultrapure water. From this, it is inferred that HCA combines with metals (such as Ca) to form Ca salts that are poorly soluble in water, and that precipitation occurs, reducing water solubility. Thus, it is suggested that the water solubility of Garcinia extract is pH-dependent, being high in acidic and neutral (pH 4-7) solutions and decreasing in alkaline (pH 9-11) solutions. [Industrial applicability]

[0065] The Garcinia extract-containing composition of the present invention can be easily used for long-term continuous use because it requires a small dosage and reduces the burden of administration, and can be widely used industrially as a product aimed at reducing body fat.

Claims

1. A composition used to promote the reduction of body fat, The above composition contains Garcinia extract as an active ingredient, A Garcinia extract-containing composition wherein the Garcinia extract contains hydroxycitric acid and / or its salt in an amount equivalent to 200 to 300 mg of hydroxycitric acid per day.

2. The Garcinia extract-containing composition according to claim 1, wherein the Garcinia extract contains hydroxycitric acid and / or a salt thereof in an amount equivalent to 250 mg of hydroxycitric acid per day.

3. The garcinia extract-containing composition according to claim 1 or 2, wherein the garcinia extract contains less than 25 mg of garcinol as a daily dose.

4. The garcinia extract-containing composition according to claim 1 or 2, wherein the garcinia extract contains a salt of hydroxycitric acid, and the salt of hydroxycitric acid is a salt of hydroxycitric acid and at least one of an alkali metal (B1) and an alkaline earth metal (B2) (B).

5. The garcinia extract-containing composition according to claim 4, wherein the garcinia extract contains 5% by mass or more of at least one of the alkali metal (B1) and alkaline earth metal (B2) (B).

6. The garcinia extract-containing composition according to claim 4, wherein the garcinia extract contains 0.5% by mass or more of calcium and / or magnesium as the alkaline earth metal (B2).

7. A method for reducing body fat, comprising administering the composition according to claim 1 or 2 for 12 weeks or more.

Images